15 results
8-K
EX-99.1
EDSA
Edesa Biotech, Inc.
3 Feb 21
Edesa Biotech Receives C$14 million for COVID-19 Study
8:00am
the potential to be an important tool in treating and preventing lung injuries caused by COVID-19. As the government continues to protect and support Canadians
424B5
EDSA
Edesa Biotech, Inc.
6 Jan 20
Prospectus supplement for primary offering
5:08pm
. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial
10-KT
EDSA
Edesa Biotech, Inc.
12 Dec 19
Annual report (with FYE transition)
4:55pm
injuries, we will incur substantial liabilities.
We have separate liability insurance policies that cover each of our ongoing clinical trials, which
10-KT
EX-14.1
vz3vd29
12 Dec 19
Annual report (with FYE transition)
4:55pm
8-K
EX-10.1
2ln090r63ftl5
30 Aug 19
Other Events
4:10pm
DEFM14A
7jw2w1b37gffrk2np0mj
18 Apr 19
Proxy related to merger
5:08pm
PREM14A
hmh8f
29 Mar 19
Preliminary proxy related to merger
4:18pm
8-K
EX-2.1
heze2 1a2
8 Mar 19
Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement
9:16am
DEFA14A
EX-2.1
qmv9270
8 Mar 19
Additional proxy soliciting materials
9:14am
20FR12G/A
EX-4.18
iil8rokuqx0hctxmhg0
5 Jul 12
Initial registration of securities (foreign private issuers) (amended)
12:00am
20FR12G
EX-4
ae4oqdlh6
3 Feb 12
Initial registration of securities (foreign private issuers)
12:00am
- Prev
- 1
- Next